<DOC>
	<DOCNO>NCT01135017</DOCNO>
	<brief_summary>Primary objective evaluate effect dronedarone Atrial Fibrillation ( AF ) burden ( i.e . percent time AF ) measure electrogram ( EGM ) subject permanent pacemaker . Secondary objective evaluate : - effect dronedarone AF pattern characteristic i.e . ventricular rate AF ; - effect dronedarone subject-perceived AF burden symptom severity report subject use Atrial Fibrillation Severity Scale ( AFSS ) ; - incidence electrical cardioversion ( overdrive pacing ) treatment ; - safety dronedarone .</brief_summary>
	<brief_title>Effects Dronedarone Atrial Fibrillation Burden Subjects With Permanent Pacemakers</brief_title>
	<detailed_description>The maximum duration study period participant 18 week ( approximatively 4.5 month ) include 4 week screen , 12-week Treatment period post-treatment follow-up 2 week .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Amiodarone</mesh_term>
	<criteria>Inclusion criterion : Paroxysmal AF atrial flutter ( AFL ) document evidence AF/AFL sinus rhythm within prior 6 month ; AF burden ≥1 % pacemaker EGM interrogation screening , least one episode AF within previous 28 day ; Programmable dual chamber pacemaker lead placement le 3 month screen , minimum capability store 3 month EGM data , expect remain battery life 1 year . Exclusion criterion : AF burden &lt; 1 % pacemaker EGM interrogation screening ; None follow cardiovascular risk factor : Age ≥70 year , hypertension , diabetes mellitus , prior cardiovascular accident systemic embolism , leave atrium diameter ≥50 mm Mmode 2D echocardiography , leave ventricular ejection fraction ≤0.40 Mmode 2D echocardiography , cardiac catheterization , nuclear cardiac imaging ; Permanent AF ; Evidence persistent AF ( continuous AF activity last long 7 day ) ; Electrical cardioversion ( overdrive pacing ) within 4 week prior screen ; Cardiac ablation procedure within 3 month prior screen ; Evidence uncorrected atrial undersensing oversensing document routine pacemaker evaluation screening ; Pacemaker programming requirement study clinically feasible , contraindicate , could pose risk ; Ongoing potentially dangerous symptom AF/AFL angina pectoris , transient ischemic attack , stroke , syncope ; New York Heart Association ( NYHA ) Class IV heart failure NYHA Class II III heart failure recent decompensation require hospitalization referral specialized heart failure clinic within 4 week prior screen ; Evidence clinical instability include hypotension , unstable angina hemodynamically significant obstructive valvular disease , hemodynamically significant obstructive cardiomyopathy , cardiac operation , revascularization procedure within 4 week prior screen ; Noncardiovascular illness disorder could preclude participation severely limit survival include cancer metastasis organ transplantation require immune suppression ; Planned noncardiac cardiac surgery procedure include surgery valvular heart disease , coronary artery bypass graft , percutaneous coronary intervention , cardiac transplantation electrical cardioversion AF/AFL ; Need concomitant medication prohibit trial : Antiarrhythmics , drug product strong inhibitor CYP3A , CYP3A inducer ; Chronic use amiodarone within 4 week prior screen ; Use Class I Class III antiarrhythmic ( amiodarone ) within 5half life prior screen ; Use St John 's wort , grapefruit juice , drug prolong QT interval might increase risk torsade de pointes ; Inability unwillingness comply oral anticoagulation therapy , indicate ; Bazett correct QT interval interval ≥500 msec screening ( sinus rhythm ) ; Uncontrolled hypertension ( systolic blood pressure ≥160 mmHg diastolic blood pressure ≥ 100mmHg ) screening ; Uncorrected hypokalemia ( serum potassium &lt; 3.5 mEq/L ) Severe hepatic impairment ( ie , ChildPugh Class C ) , abnormal liver function test define alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , bilirubin &gt; 2 X upper limit normal ( ULN ) , renal impairment define serum creatinine &gt; 2.0 mg/dL screening ; Uncontrolled diabetes mellitus ( documented history HbA1c &gt; 10 % recent assessment prior screen ) ; Pregnant woman woman childbearing potential adequate birth control ; Breastfeeding woman ; Previous ( within 2 month prior screen ) current participation another clinical trial investigational drug ( development ) investigational device . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>